Ocular Therapeutix (OCUL) Depreciation & Amortization (CF) (2013 - 2026)
Ocular Therapeutix's quarterly Depreciation & Amortization (CF) came in at $1.3 million in Q1 2026, up 30.78% year-on-year from $981000.0 in Q1 2025, and up 2.89% quarter-over-quarter from $1.2 million in Q4 2025.
Ocular Therapeutix has reported Depreciation & Amortization (CF) for 14 years, with the latest figure at $1.3 million in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 30.78% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $4.6 million (up 20.36% YoY), and the FY2025 full-year result was $4.3 million, up 14.18% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $1.3 million, up from $1.2 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $1.3 million in Q1 2026, with the low at $483000.0 in Q1 2023.
- Average Depreciation & Amortization (CF) over 5 years is $852176.5, with a median of $951000.0 recorded in 2024.
- Year-over-year, Depreciation & Amortization (CF) fell 14.31% in 2022 and jumped 95.11% in 2023.
- Tracing OCUL's Depreciation & Amortization (CF) over 5 years: stood at $491000.0 in 2022, then surged by 95.11% to $958000.0 in 2023, then dropped by 0.73% to $951000.0 in 2024, then soared by 31.13% to $1.2 million in 2025, then advanced by 2.89% to $1.3 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $1.3 million (Q1 2026), $1.2 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | 1.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.28 Mn |
| Mar 31, 2026 | 1.28 Mn |
| Dec 31, 2025 | 1.25 Mn |
| Dec 31, 2025 | 1.25 Mn |
| Sep 30, 2025 | 1.07 Mn |
| Sep 30, 2025 | 1.07 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | 981,000.00 |
| Mar 31, 2025 | 981,000.00 |
| Dec 31, 2024 | 951,000.00 |
| Dec 31, 2024 | 951,000.00 |
| Sep 30, 2024 | 958,000.00 |
| Sep 30, 2024 | 958,000.00 |
| Jun 30, 2024 | 956,000.00 |
| Jun 30, 2024 | 956,000.00 |
| Mar 31, 2024 | 920,000.00 |
| Mar 31, 2024 | 920,000.00 |
| Dec 31, 2023 | 958,000.00 |
| Dec 31, 2023 | 958,000.00 |
| Sep 30, 2023 | 890,000.00 |
| Sep 30, 2023 | 890,000.00 |
| Jun 30, 2023 | 652,000.00 |
| Jun 30, 2023 | 652,000.00 |
| Mar 31, 2023 | 483,000.00 |
| Mar 31, 2023 | 483,000.00 |
| Dec 31, 2022 | 491,000.00 |
| Dec 31, 2022 | 491,000.00 |
| Sep 30, 2022 | 509,000.00 |
| Sep 30, 2022 | 509,000.00 |
| Jun 30, 2022 | 552,000.00 |
| Jun 30, 2022 | 552,000.00 |
| Mar 31, 2022 | 557,000.00 |
| Mar 31, 2022 | 557,000.00 |
| Dec 31, 2021 | 570,000.00 |
| Dec 31, 2021 | 570,000.00 |
| Sep 30, 2021 | 594,000.00 |
| Sep 30, 2021 | 594,000.00 |
| Jun 30, 2021 | 611,000.00 |
| Jun 30, 2021 | 611,000.00 |
| Mar 31, 2021 | 646,000.00 |
| Mar 31, 2021 | 646,000.00 |
| Dec 31, 2020 | 667,000.00 |
| Dec 31, 2020 | 667,000.00 |
| Sep 30, 2020 | 665,000.00 |
| Sep 30, 2020 | 665,000.00 |
| Jun 30, 2020 | 707,000.00 |
| Jun 30, 2020 | 707,000.00 |
| Mar 31, 2020 | 734,000.00 |
| Mar 31, 2020 | 734,000.00 |
| Dec 31, 2019 | 674,000.00 |
| Dec 31, 2019 | 674,000.00 |
| Sep 30, 2019 | 669,000.00 |
| Sep 30, 2019 | 669,000.00 |
| Jun 30, 2019 | 598,000.00 |
| Jun 30, 2019 | 598,000.00 |
| Mar 31, 2019 | 589,000.00 |
| Mar 31, 2019 | 589,000.00 |
| Dec 31, 2018 | 582,000.00 |
| Dec 31, 2018 | 582,000.00 |
| Sep 30, 2018 | 573,000.00 |
| Sep 30, 2018 | 573,000.00 |
| Jun 30, 2018 | 566,000.00 |
| Jun 30, 2018 | 566,000.00 |
| Mar 31, 2018 | 565,000.00 |
| Mar 31, 2018 | 565,000.00 |
| Dec 31, 2017 | 528,000.00 |
| Dec 31, 2017 | 528,000.00 |
| Sep 30, 2017 | 482,000.00 |
| Sep 30, 2017 | 482,000.00 |
| Jun 30, 2017 | 354,000.00 |
| Jun 30, 2017 | 354,000.00 |
| Mar 31, 2017 | 261,000.00 |
| Mar 31, 2017 | 261,000.00 |
| Dec 31, 2016 | 253,000.00 |
| Dec 31, 2016 | 253,000.00 |
| Sep 30, 2016 | 216,000.00 |
| Sep 30, 2016 | 216,000.00 |
| Jun 30, 2016 | 207,000.00 |
| Jun 30, 2016 | 207,000.00 |
| Mar 31, 2016 | 205,000.00 |
| Mar 31, 2016 | 205,000.00 |
| Dec 31, 2015 | 200,000.00 |
| Dec 31, 2015 | 200,000.00 |
| Sep 30, 2015 | 194,000.00 |
| Sep 30, 2015 | 194,000.00 |
| Jun 30, 2015 | 187,000.00 |
| Jun 30, 2015 | 187,000.00 |
| Mar 31, 2015 | 173,000.00 |
| Mar 31, 2015 | 173,000.00 |
| Dec 31, 2014 | 164,000.00 |
| Dec 31, 2014 | 164,000.00 |
| Sep 30, 2014 | 139,000.00 |
| Sep 30, 2014 | 139,000.00 |
| Jun 30, 2014 | 151,000.00 |
| Jun 30, 2014 | 151,000.00 |
| Mar 31, 2014 | 93,000.00 |
| Mar 31, 2014 | 93,000.00 |
| Sep 30, 2013 | 92,000.00 |
| Sep 30, 2013 | 92,000.00 |